Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
Authors
Keywords
-
Journal
EYE
Volume 29, Issue 4, Pages 534-541
Publisher
Springer Nature
Online
2015-01-30
DOI
10.1038/eye.2014.338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration
- (2013) Jerrod S. Kent et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- High-dose (2.0 mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
- (2013) Paul T. Finger et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
- (2013) David M. Brown et al. OPHTHALMOLOGY
- SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results
- (2013) Charles C. Wykoff et al. Ophthalmic Surgery Lasers & Imaging Retina
- Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
- (2012) Tim U. Krohne et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema
- (2012) Ranjan Rajendram et al. ARCHIVES OF OPHTHALMOLOGY
- Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
- (2012) Jie Ding et al. Current Diabetes Reports
- Zytokinbestimmung aus Glaskörperproben bei retinalen Gefäßerkrankungen
- (2012) M. Pfister et al. OPHTHALMOLOGE
- Biological, Preclinical and Clinical Characteristics of Inhibitors of Vascular Endothelial Growth Factors
- (2012) Victor Chong OPHTHALMOLOGICA
- Ranibizumab for Diabetic Macular Edema
- (2012) Quan Dong Nguyen et al. OPHTHALMOLOGY
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
- (2012) Michael J. Elman et al. OPHTHALMOLOGY
- Ranibizumab for Edema of the Macula in Diabetes Study
- (2012) Diana V. Do JAMA Ophthalmology
- Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
- (2011) Michael J. Elman et al. OPHTHALMOLOGY
- The RESTORE Study
- (2011) Paul Mitchell et al. OPHTHALMOLOGY
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study
- (2010) P. Massin et al. DIABETES CARE
- Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes Previously Treated with Alternative Vascular Endothelial Growth Factor Inhibitors
- (2010) Justis P. Ehlers et al. OPHTHALMIC SURGERY LASERS & IMAGING
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
- (2010) Quan Dong Nguyen et al. OPHTHALMOLOGY
- INTRAVITREAL BEVACIZUMAB AND/OR MACULAR PHOTOCOAGULATION AS A PRIMARY TREATMENT FOR DIFFUSE DIABETIC MACULAR EDEMA
- (2010) Kamal A M Solaiman et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema
- (2009) J. Fernando Arevalo et al. OPHTHALMOLOGY
- Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema
- (2009) Masoud Soheilian et al. OPHTHALMOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now